[Clinical use of growth hormone and clonidine in growth disorders].
The aim of this study was to investigate the effects of the recombinant human growth hormone and of the alpha-2 adrenergic agonist clonidine in three groups of prepuberal children with growth disorders. Three children with GH-deficiency were treated with 0.5 U kg/week i.m. of recombinant growth hormone; 13 children (7 with constitutional delay of growth and 6 with familiar short stature) were treated with 0.08 mg/m2/die per os of clonidine. The results confirmed the growth promoting effect of GH in GH-deficiency. Clonidine restored GH-secretion in children with constitutional delay, but had a very poor or no effect in familiar short children.